Stocks · News reference
Wells Fargo analyst James Feldman maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Overweight and lowers the price target from $23 to $21.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Sabra Health Care raised its full-year normalized FFO guidance and is rebalancing its portfolio toward senior housing operations, targeting 50% of assets by late 2027. The company expects rent increases from skilled nursing lease resets through 2031 and is managing leverage while funding growth through strategic capital allocation.
Sabra Health Care REIT, Inc. announced its financial results for the third quarter of 2026 and provided an update to its full-year 2026 guidance.
UBS analyst Michael Goldsmith maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and lowers the price target from $21 to $20.
Barclays analyst Richard Hightower maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Equal-Weight and lowers the price target from $23 to $21.
Barclays analyst Richard Hightower maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Equal-Weight and raises the price target from $21 to $23.
Baird analyst Vikram Malhotra maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and raises the price target from $20 to $21.